1. Forms of Selenium.- 1.1 Low Molecular-Weight Compounds.- 1.1.1 Selenocysteine.- 1.1.2 Selenocystine.- 1.1.3 Selenohomocystine.- 1.1.4 Se-methylselenocysteine.- 1.1.5 Selenocystathionine.- 1.1.6 Selenomethionine.- 1.1.7 Se-methylselenomethionine.- 1.1.8 Dimethyl Selenide.- 1.1.9 Dimethyl Diselenide.- 1.1.10 Trimethyl Selenonium.- 1.1.11 Elemental Selenium.- 1.1.12 Selenotaurine.- 1.1.13 Selenocoenzyme A.- 1.1.14 Other Compounds.- 1.2 Macromolecular Forms of Selenium.- 1.2.1 Formate Dehydrogenase.- 1.2.2 Glycine Reductase.- 1.2.3 Nicotinic Acid Hydroxylase.- 1.2.4 Xanthine Hydrogenase.- 1.2.5 Thiolase.- 1.2.6 Glutathione Peroxidase.- 1.2.7 Miscellaneous Selenoproteins.- 1.2.8 Seleno-tRNA's.- 11.11 References.- 2. Selenium Deficiency Diseases in Animals.- 2.1 Introduction.- 2.2 Dietary Liver Necrosis and Factor 3.- 2.2.1 Discovery.- 2.2.2 Pathology.- 2.2.3 Biochemical Defect.- 2.2.4 Hepatosis Dietetica.- 2.3 Nutritional Muscular Dystrophy.- 2.3.1 Pathology.- 2.3.2 Prevention of NMD.- 2.4 Exudative Diathesis.- 2.5 Pancreatic Degeneration.- 2.6 Mulberry Heart Disease.- 2.7 Reproductive Problems.- 2.8 Myopathy of the Gizzard.- 2.9 Growth.- 2.10 Selenium-Responsive Unthriftiness of Sheep and Cattle.- 2.11 Periodontal Disease of Ewes.- 2.12 Encephalomalacia.- 11.11 References.- 3. Metabolism of Selenium.- 3.1 Absorption.- 3.2 Placental Transfer.- 3.3 Mechanism of the Antioxidant Action of Selenium.- 3.4 Effect of Paraquat.- 3.5 Effect on Cytochrome P-450.- 3.6 Selenium and Hepatic Heme Metabolism.- 11.11 References.- 4. Comparative Metabolism and Biochemistry of Selenium and Sulphur.- 4.1 Introduction.- 4.2 Comparative Metabolism of Selenium and Sulphur.- 4.2.1 Microorganisms.- 4.2.2 Plants.- 4.2.3 Animals.- 4.3 Comparative Biochemistry of Selenium and Sulphur.- 4.3.1 Selenopersulfide as an Electron Transfer Catalyst.- 4.3.2 Iron-Sulphur Proteins.- 4.3.3 Sulphur Salts and Selenium Toxicity in Animals.- 4.3.4 Other Selenium-Sulphur Interactions.- 11.11 References.- 5. Biological Interactions of Selenium with Other Substances.- 5.1 Cadmium.- 5.1.1 Pathological Effects.- 5.1.2 Cadmium-Zinc Interactions.- 5.1.3 Cadmium-Selenium Interactions.- 5.1.4 Effect on Drug Response.- 5.2 Arsenic.- 5.3 Copper.- 5.4 Silver.- 5.5 Cobalt.- 5.6 Manganese.- 5.7 Lead.- 5.8 Mercury.- 5.8.1 Inorganic and Organic Mercury.- 5.8.2 Tissue Distribution.- 5.8.3 Properties of the Mercury-Selenium Complex.- 5.8.4 Teratogenicity.- 5.9 Thallium.- 5.10 Tellurium.- 5.11 Vanadium.- 5.12 Bismuth.- 5.13 Other Substances.- 11.11 References.- 6. Environmental Occurrence of Selenium.- 6.1 Geochemistry of Selenium.- 6.2 Soil Selenium.- 6.3 Uptake and Concentration of Trace Elements in the Roots, Stems, and Leaves of Plants.- 6.4 Forage Selenium.- 6.5 Selenium in Water.- 6.6 Selenium in Food.- 6.7 Intakes and Recommended Daily Allowance in Humans.- 6.8 Regulations in Regard to Animal Diets.- 11.11 References.- 7. Toxicity of Selenium.- 7.1 Introduction.- 7.1.1 Acute Toxicity.- 7.1.2 Blind Staggers.- 7.1.3 Alkalai Disease.- 7.1.4 Toxicity in Rabbits.- 7.1.5 Toxicity in Hamsters.- 7.1.6 Toxicity in Sheep.- 7.1.7 Toxicity in Rats.- 7.1.8 Effect of Diet on Toxicity.- 7.1.9 Biochemical Lesions.- 7.1.10 LD50 of Various Selenium Compounds.- 7.2 Industrial Medical Aspects.- 7.2.1 Occupational Hazards.- 7.2.2 Permissible Limits for Selenium Exposure.- 7.2.3 Toxicity in Humans.- 11.11 References.- 8. Selenium in Health and Disease.- 8.1 Selenium and Cancer.- 8.1.1 Skin Cancer.- 8.1.2 Liver Cancer.- 8.1.3 Colon Cancer.- 8.1.4 Breast Cancer.- 8.1.5 Tracheal Cancer.- 8.1.6 Chemotherapeutic Effect of Selenium.- 8.1.7 Epidemiological Relationship.- 8.1.8 Selenium Blood Levels in Cancer Patients.- 8.1.9 Selenium as a Carcinogen.- 8.2 Selenium and Mutagenesis.- 8.2.1 Antimutagenicity.- 8.2.2 Mutagenicity.- 8.3 Selenium and Immunity.- 8.3.1 Effect of Selenium on Humoral Immunity.- 8.3.2 Cell-Mediated Immunity.- 8.3.3 Nonspecific Immune Effects of Selenium.- 8.4 Selenium and Dental Caries.- 8.5 The Anti-Inflammatory Properties of Selenium.- 8.6 Selenium and Heart Disease.- 8.6.1 Animals.- 8.6.2 Humans.- 8.7 Selenium and Aging.- 8.8 Cystic Fibrosis.- 8.9 Multiple Sclerosis.- 8.10 Cataracts.- 8.11 Other Diseases.- 8.12 Radioselenium as a Diagnostic Agent.- 11.11 References.- 9. Synthetic Forms of Selenium and Their Chemotherapeutic Uses.- 9.1 Anti-Infective Agents.- 9.1.1 Antibacterial.- 9.1.2 Antiviral.- 9.2 Antifungal Agents.- 9.3 Antiparasitic Agents.- 9.4 Compounds Affecting the Central Nervous System.- 9.4.1 Hypnotics.- 9.4.2 Analgesics and Local Anesthetics.- 9.4.3 Tranquilizing Drugs.- 9.5 Compounds that Affect the Autonomic Nervous System.- 9.6 Compounds that Affect the Circulatory System.- 9.7 Anti-Inflammatory Compounds.- 9.8 Antihistamines.- 9.9 Anticancer Agents.- 9.10 Antiradiation Agents.- 9.11 Steroids.- 9.12 Selenocoenzyme A.- 9.13 Selenium-Containing Carbohydrates.- 9.14 Seleno-Amino Acids.- 11.11 References.- 10. Analytical Methods of Selenium Determination.- 10.1 Introduction.- 10.2 Sample Preparation and Storage.- 10.3 Destructive Analysis.- 10.3.1 Ashing.- 10.3.2 Closed-System Combustion.- 10.3.3 Wet Digestion.- 10.3.4 Measurement of Selenium.- 10.4 Nondestructive Analysis.- 10.4.1 Neutron Activation Analysis.- 10.4.2 X-Ray Fluorescence Analysis.- 10.4.3 Proton-Induced X-Ray Emission.- References.

/pdf/biochemistry-of-selenium-gu73q1uo0t.pdf

Biochemistry of selenium.

Radioprotection by antioxidant enzymes and enzyme mimetics

To establish guidelines for the selenium supplementation in radiotherapy we assessed the benefits and risks of selenium supplementation in radiotherapy. Clinical studies on the use of selenium in radiotherapy were searched in the PubMed electronic database in January 2013. Sixteen clinical studies were identified among the 167 articles selected in the initial search. Ten articles were observational studies, and the other 6 articles reported studies on the effects of selenium supplementation in patients with cancer who underwent radiotherapy. The studies were conducted worldwide including European, American and Asian countries between 1987 and 2012. Plasma, serum or whole blood selenium levels were common parameters used to assess the effects of radiotherapy and the selenium supplementation status. Selenium supplementation improved the general conditions of the patients, improved their quality of life and reduced the side effects of radiotherapy. At the dose of selenium used in these studies (200–500 μg/day), selenium supplementation did not reduce the effectiveness of radiotherapy, and no toxicities were reported. Selenium supplementation may offer specific benefits for several types of cancer patients who undergo radiotherapy. Because high-dose selenium and long-term supplementation may be unsafe due to selenium toxicity, more evidence-based information and additional research are needed to ensure the therapeutic benefits of selenium supplementation.

/pdf/updates-on-clinical-studies-of-selenium-supplementation-in-52y5fq2p8r.pdf

Updates on clinical studies of selenium supplementation in radiotherapy

Radioprotection by metals: selenium.

Although WR-2721, S-2-(3-aminopropylamino)ethylphosphorothioic acid, is an effective radioprotector, its use is limited by its toxicity. Combining WR-2721 with other agents might decrease its toxicity and/or increase its effectiveness. The effect of selenium (Se) pretreatment on the acute toxicity and radioprotective effect of WR-2721 was studied in male CD2F1 mice. Injection of 1.6mg/kg Se 24 hr before WR-2721 (800-1200 mg/kg, IP) decreased the lethality of WR-2721 significantly. Lower doses of Se were also effective, but simultaneous administration was not effective. Se injection alone (1.6 mg/kg) 24 hr before cobalt-60 irradiation increased the survival (dose reduction factor, DRF = 1.1) significantly. A synergistic effect on post-irradiation survival was observed when Se was injected 24 hr before WR-2721 (200-600 mg/ kg IP before irradiation). For example, after exposure to 22 Gy (1 Gy/min), 30-day survival was 100% when mice were treated with both Se and 600mg/kg WR-2721, and was 13% with WR-2721 alo...

Selenium pretreatment enhances the radioprotective effect and reduces the lethal toxicity of WR-2721.

This paper deals with the radioprotection afforded by selenocystine, selenomethionine, colloidal selenium, selenoxanthene, selenoxanthone, and selenochromone in living rats. Our evaluation of radioprotection was based on the ability of the compounds to alleviate the mortality and the leukopenia occurring in rats exposed to irradiation of 600, 750, and 900 R. The results show that these compounds have an action similar to, and sometimes even superior to, that of cysteine. A preliminary study was made of the mechanism of action of the selenium derivatives by measurement of the retention of selenium in the blood, and its distribution at the subcellular level in the liver.

On the chemical radioprotection by organic selenium compounds in vivo.

Abstract This paper deals with a study of some tests in rats in vivo after gamma irradiation in the presence and in the ab sence of selenourea. The factors considered were the total protein content, the protein pattern, and some serum enzymes, like GOT, GPT and AP. The result shows that the preadministration of selenourea modifies fovourably the changes induced by ionizing radiation

Further observations on in vivo radioprotection of rats by selenourea.

Die Geschwindigkeit der Verteilung und Fixierung des Selenharnstoff-75Se wurde in diversen Rattenorganen in vivo und bei Stoffwechselzeiten von 6 h bis zu 14 Tagen untersucht. Die Selenharnstoffmengen varierten zwischen 0,4 und 3,0 mg pro Tier.

Mattii M

Papers

On the chemical radioprotection by organic selenium compounds in vivo.

Further observations on in vivo radioprotection of rats by selenourea.

Rate of uptake of75Se, as selenourea-75Se, in rats in vivo